Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 18;9(1):2367.
doi: 10.1038/s41467-018-04814-4.

Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients

Jianguang Ji  1 , Jan Sundquist  2   3 , Kristina Sundquist  2   3
Affiliations

Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients

Jianguang Ji et al. Nat Commun. .

Abstract

Recent evidence suggests that cholera toxin might have multiple functions regarding the ability to regulate the immune system. However, it is unknown whether subsequent administration of cholera vaccine might affect the mortality rate in patients with prostate cancer. Here we report that patients in Sweden, who were diagnosed with prostate cancer between July 2005 and December 2014 and used cholera vaccine, have a decreased risk of death from prostate cancer (HR, 0.57; 95% CI, 0.40-0.82) as compared to patients with prostate cancer but without cholera vaccine use, adjusted for a range of confounding factors. In addition, patients using cholera vaccine show a decreased risk of death overall (HR, 0.53; 95% CI, 0.41-0.69). The decreased mortality rate is largely consistent, irrespective of patients' age or tumor stage at diagnosis. In this population-based study, we suggest that subsequent administration of cholera vaccine after prostate cancer diagnosis might reduce the mortality rate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A nonparametric estimate of the hazard ratio as a function of follow-up time
See this image and copyright information in PMC

References

    1. De Angelis R, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014;15:23–34. doi: 10.1016/S1470-2045(13)70546-1. - DOI - PubMed
    1. Jemal A, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J. Natl Cancer. Inst. 2017;109:djx030. doi: 10.1093/jnci/djx030. - DOI - PMC - PubMed
    1. Doulberis M, et al. Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer. Carcinogenesis. 2015;36:280–290. doi: 10.1093/carcin/bgu325. - DOI - PMC - PubMed
    1. Bharati K, Ganguly NK. Cholera toxin: a paradigm of a multifunctional protein. Indian J. Med. Res. 2011;133:179–187. - PMC - PubMed
    1. Baldauf KJ, et al. Cholera toxin B: one subunit with many pharmaceutical applications. Toxins. 2015;7:974–996. doi: 10.3390/toxins7030974. - DOI - PMC - PubMed

Publication types

Substances